Journal for ImmunoTherapy of Cancer · 2020 · 33 citations · 17 references
MedicineOncologyPharmacologyChemotherapyImmunogeneticsTumor ImmunologyCancer BiomarkersCancer GenomicsCancer ImmunotherapyCancer PharmacogenomicsColorectal CancerMalignant NeoplasmsChemotherapy-induced Immunogenic Cell DeathClinical Cohort DiscoveryGenetic Prognostic MarkersGenomic Dna AnalysisImmunogenic Cell Death InductionOxaliplatin-based TherapyRandomized Clinical TrialsSingle-nucleotide Polymorphisms
Background Immunogenic cell death (ICD) is a tumor cell death involving both innate and adaptive immune responses. Given published findings that oxaliplatin, but not irinotecan, drives ICD, we investigated whether single nucleotide polymorphisms (SNPs) in the ICD pathway are associated with the efficacy of oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC). Methods Two randomized clinical trials data were analyzed: discovery cohort, FOLFOX/bevacizumab arm (MAVERICC); validation cohort, FOLFOXIRI/bevacizumab arm (TRIBE); and two control cohorts, FOLFIRI/bevacizumab arms (both trials). Genomic DNA extracted from blood samples was genotyped. Ten SNPs in the ICD pathway were tested for associations with clinical outcomes. Results In total, 648 patients were included. In the discovery cohort, three SNPs were significantly associated with clinical outcomes in univariate analysis: CALR rs1010222 with progression-free survival (G/G vs any A, HR=0.61, 95% CI 0.43–0.88), ANXA1 rs1050305 with overall survival (OS) (A/A vs any G, HR=1.87, 95% CI 1.04–3.35), and LRP1 rs1799986 with OS (C/C vs any T, HR=1.69, 95% CI 1.07–2.70). Multivariate analysis confirmed the trend, but statistical significance was not reached. In the validation cohort, ANXA1 rs1050305, and LRP1 rs1799986 were validated to have the significant associations with clinical outcome. No significant associations of these SNPs were observed in the two control cohorts. Treatment-by-SNP interaction test confirmed the predictive values. Conclusions The predictive utility of ICD-related SNPs for the efficacy of oxaliplatin-based chemotherapy was demonstrated, warranting further validation studies to be translated into personalized treatment strategies using conventional cytotoxic agents in mCRC.
17
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Eric Van Cutsem, Andrés Cervantes, René Adam et al. · Annals of Oncology · 2016 · 3.4K citations · Full text
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obéid, Antoine Tesnière, François Ghiringhelli et al. · Nature Medicine · 2006 · 3.1K citations
Medicine, Immunology, Oncology +14
Immunogenic death of colon cancer cells treated with oxaliplatin
Antoine Tesnière, F. Schlemmer, Valérie Boige et al. · Oncogene · 2009 · 1.1K citations
Medicine, Oncology, Pharmacology +14
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis, Chiara Cremolini, Gianluca Masi et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text
Medicine, Oncology, Pharmacotherapy +12